Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,deferredLongTermLiab,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,postMarketChangePercent,postMarketTime,postMarketPrice,postMarketChange,regularMarketChangePercent,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,priceEpsCurrentYear,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsCurrentYear,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GMTX,171161000.0,43052900,11786000,,-19048000,,-19048000,4704000,0,-16490000,-16490000,,-1848000,,,,0,0,16490000,0,-2558000,,-19048000,-19048000,303026000.0,18221000.0,171161000.0,189382000.0,4000.0,-131869000.0,316000.0,548000.0,184986000.0,13776000.0,5000000.0,229000.0,188605000.0,4129000.0,3562000.0,,2173000.0,-833000.0,195490000.0,-2289000.0,4000.0,180483000.0,-15007000.0,65000.0,196319000.0,2492000.0,,,174829000.0,en-US,US,EQUITY,True,Delayed Quote,391357,1.8599999,0.5776397,3.22 - 19.085,-14.004999,-0.73382235,3.22,19.085,1617048000,1617048000,1617048000,4.2188573,0.86114264,0.2041175,9.937862,-4.8578625,218708736,2,-0.39370042,1630540578,5.06,-0.01999998,3.2520294,15,America/New_York,EDT,-14400000,4.85 - 5.18,4.92,0.0,0.0,8,9,finmb_333301486,NasdaqGM,"Gemini Therapeutics, Inc.",USD,500490,-2.5918367,USD,False,False,5.08,1630526403,0.15999985,4.92,5.18,4.85,540531,NGM,"Gemini Therapeutics, Inc.",0,us_market,PREPRE,-1.96,-0.48882368,,,,19.08,3.22,4.22,9.94,500.49k,391.36k,43.05M,,21.97M,22.75%,72.24%,1.17M,7.29,5.27%,2.73%,1.16M,,,,,,,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.82%,-62.36%,,,,,-40.59M,-50.14M,,,184.99M,4.3,9.13M,5.33,13.69,,-37.83M,-20.39M,Value,02139,Healthcare,29,"Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.",Cambridge,212 600 1902,MA,1609372800,United States,http://www.geminitherapeutics.com,86400,300 One Kendall Square,Biotechnology,3rd Floor
t-1,GMTX,-102310000.0,43052900,8597000,,-14315000,,-14315000,1197000,0,-9794000,-9794000,,-4519000,,,,0,0,9794000,0,-4521000,,-14315000,-14315000,10504000.0,30104000.0,-102310000.0,8319000.0,7000.0,-112821000.0,277000.0,2960000.0,4503000.0,24876000.0,5000000.0,294000.0,5065000.0,4951000.0,2377000.0,2637000.0,-930000.0,-833000.0,141000.0,1291000.0,141000.0,-8712000.0,-8853000.0,87000.0,-16000.0,926000.0,,,-19811000.0,en-US,US,EQUITY,True,Delayed Quote,391357,1.8599999,0.5776397,3.22 - 19.085,-14.004999,-0.73382235,3.22,19.085,1617048000,1617048000,1617048000,4.2188573,0.86114264,0.2041175,9.937862,-4.8578625,218708736,2,-0.39370042,1630540578,5.06,-0.01999998,3.2520294,15,America/New_York,EDT,-14400000,4.85 - 5.18,4.92,0.0,0.0,8,9,finmb_333301486,NasdaqGM,"Gemini Therapeutics, Inc.",USD,500490,-2.5918367,USD,False,False,5.08,1630526403,0.15999985,4.92,5.18,4.85,540531,NGM,"Gemini Therapeutics, Inc.",0,us_market,PREPRE,-1.96,-0.48882368,,,,19.08,3.22,4.22,9.94,500.49k,391.36k,43.05M,,21.97M,22.75%,72.24%,1.17M,7.29,5.27%,2.73%,1.16M,,,,,,,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.82%,-62.36%,,,,,-40.59M,-50.14M,,,184.99M,4.3,9.13M,5.33,13.69,,-37.83M,-20.39M,Value,02139,Healthcare,29,"Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.",Cambridge,212 600 1902,MA,1609372800,United States,http://www.geminitherapeutics.com,86400,300 One Kendall Square,Biotechnology,3rd Floor
t-2,GMTX,-88727000.0,43052900,6792000,,-10003000,,-10003000,1157000,0,-7949000,-7949000,,-2047000,,,,0,0,7949000,0,-2054000,,-10003000,-10003000,9773000.0,24457000.0,-88727000.0,16253000.0,6000.0,-98506000.0,234000.0,1666000.0,13215000.0,18033000.0,3750000.0,381000.0,14206000.0,6190000.0,2936000.0,1341000.0,-533000.0,14000000.0,14003000.0,1395000.0,3000.0,7040000.0,-6941000.0,80000.0,-16000.0,342000.0,-22000.0,-22000.0,-3827000.0,en-US,US,EQUITY,True,Delayed Quote,391357,1.8599999,0.5776397,3.22 - 19.085,-14.004999,-0.73382235,3.22,19.085,1617048000,1617048000,1617048000,4.2188573,0.86114264,0.2041175,9.937862,-4.8578625,218708736,2,-0.39370042,1630540578,5.06,-0.01999998,3.2520294,15,America/New_York,EDT,-14400000,4.85 - 5.18,4.92,0.0,0.0,8,9,finmb_333301486,NasdaqGM,"Gemini Therapeutics, Inc.",USD,500490,-2.5918367,USD,False,False,5.08,1630526403,0.15999985,4.92,5.18,4.85,540531,NGM,"Gemini Therapeutics, Inc.",0,us_market,PREPRE,-1.96,-0.48882368,,,,19.08,3.22,4.22,9.94,500.49k,391.36k,43.05M,,21.97M,22.75%,72.24%,1.17M,7.29,5.27%,2.73%,1.16M,,,,,,,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.82%,-62.36%,,,,,-40.59M,-50.14M,,,184.99M,4.3,9.13M,5.33,13.69,,-37.83M,-20.39M,Value,02139,Healthcare,29,"Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.",Cambridge,212 600 1902,MA,1609372800,United States,http://www.geminitherapeutics.com,86400,300 One Kendall Square,Biotechnology,3rd Floor
t-3,GMTX,-70797000.0,43052900,8217000,,-9746000,,-9746000,1414000,0,-9631000,-9631000,,-153000,,,,0,0,9631000,0,-115000,,-9746000,-9746000,1433000.0,15134000.0,-70797000.0,8585000.0,6000.0,-88503000.0,190000.0,325000.0,6175000.0,7516000.0,2500000.0,461000.0,7799000.0,7428000.0,2874000.0,,715000.0,14000000.0,20094000.0,-1114000.0,10000.0,10213000.0,-9881000.0,77000.0,-16000.0,187000.0,-22000.0,-22000.0,283000.0,en-US,US,EQUITY,True,Delayed Quote,391357,1.8599999,0.5776397,3.22 - 19.085,-14.004999,-0.73382235,3.22,19.085,1617048000,1617048000,1617048000,4.2188573,0.86114264,0.2041175,9.937862,-4.8578625,218708736,2,-0.39370042,1630540578,5.06,-0.01999998,3.2520294,15,America/New_York,EDT,-14400000,4.85 - 5.18,4.92,0.0,0.0,8,9,finmb_333301486,NasdaqGM,"Gemini Therapeutics, Inc.",USD,500490,-2.5918367,USD,False,False,5.08,1630526403,0.15999985,4.92,5.18,4.85,540531,NGM,"Gemini Therapeutics, Inc.",0,us_market,PREPRE,-1.96,-0.48882368,,,,19.08,3.22,4.22,9.94,500.49k,391.36k,43.05M,,21.97M,22.75%,72.24%,1.17M,7.29,5.27%,2.73%,1.16M,,,,,,,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.82%,-62.36%,,,,,-40.59M,-50.14M,,,184.99M,4.3,9.13M,5.33,13.69,,-37.83M,-20.39M,Value,02139,Healthcare,29,"Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD) and linked ocular disorders. Its lead candidate is GEM103, a recombinant form of the human complement factor H protein that is in a Phase 2a trials in dry AMD patients with a complement factor H protein risk variant. The company was founded in 2015 and is based in Cambridge, Massachusetts.",Cambridge,212 600 1902,MA,1609372800,United States,http://www.geminitherapeutics.com,86400,300 One Kendall Square,Biotechnology,3rd Floor
